HEXO Corp.

NasdaqCM:HEXO Stock Report

Market Cap: US$30.4m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

HEXO Past Earnings Performance

Past criteria checks 0/6

HEXO's earnings have been declining at an average annual rate of -42.2%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 39.8% per year.

Key information

-42.20%

Earnings growth rate

-4.54%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth rate39.79%
Return on equity-191.40%
Net Margin-220.13%
Last Earnings Update30 Apr 2023

Recent past performance updates

Recent updates

Seeking Alpha Aug 30

Hexo to produce Mike Tyson's cannabis brand's products in Canada

Hexo (NASDAQ:HEXO) said it signed an exclusive partnership with Mike Tyson's recently formed cannabis company TYSON 2.0. Under the agreement, Hexo will produce TYSON 2.0's products in Canada, including full range of flower, pre-rolls, edibles and vapes. The HEXO-produced lines will launch across Canada in fall 2022, the company said in an Aug. 30 press release. "With their broad product range from flower to straight edge pre-rolls to edibles, the TYSON 2.0 brand fits perfectly into HEXO's market leading portfolio," said Hexo CEO Charlie Bowman. HEXO +4.67% to $0.22 premarket Aug. 30
Seeking Alpha Aug 17

Canopy Growth, Tilray other Canadian cannabis names up amid WallStreetBets chatter

Canopy Growth (NASDAQ:CGC), Tilray Brands (NASDAQ:TLRY), and other Canadian cannabis licensed producers are markedly higher in Wednesday trading as chatter about the industry on WallStreetBets intensifies. In Wednesday morning trading, Canopy (CGC) is up 11%, Tilray (TLRY) up 4%, Aurora Cannabis (NASDAQ:ACB) up 6%, and HEXO Corp. (NASDAQ:HEXO) up 11%. There is increased discussion about Canadian LPs on WallStreetBets which may account for the increases. Tilray (TLRY) CEO Irwin Simon, in a recent interview with Yahoo Finance, said that the U.S. represents in $100B opportunity in cannabis. That opportunity could become reality if a federal marijuana legalization bill gets signed into law. Check out a recent deep dive into Tilray (TLRY) and whether the stock is a buy at this time.
Seeking Alpha Jul 28

HEXO receives additional 180 calendar day grace period for regaining compliance

HEXO (NASDAQ:HEXO) received an extension of 180 calendar days post expiration of initial 180 calendar days period to regain minimum bid price requirement compliance on July 25, 2022 from the Nasdaq Stock Market. The company now has time until Jan.23, 2023 to regain compliance after which the company is likely to receive notification for shares delisting. The current notification has no impact on the listing.
Seeking Alpha Jul 05

HEXO wins shareholder approval for note transaction with Tilray

Canadian cannabis player HEXO Corp (NASDAQ:HEXO) announced on Tuesday that the company’s shareholders voted in favor of its previously disclosed transaction of convertible notes with its domestic rival Tilray (TLRY). ~87% of votes were in favor of approving certain terms of the deal, the company said following a reconvened special meeting of shareholders today. ~18% of the company’s common shares were represented at the meeting, which was initially scheduled for June 14. However, the meeting was adjourned to provide investors more time to evaluate the previously announced amendments to the transaction. Under the deal anticipated to close in 3Q 2022, Tilray (TLRY) is set to purchase as much as $185M of debt Hexo (HEXO) has issued to funds affiliated with HT Investments.
Seeking Alpha Apr 28

HEXO: Undervalued, But With Certain Dilution Risks

HEXO Corp. runs a consumer packaged goods cannabis business model with a leader position in the Canadian market and a production capacity of 150,000 kgs. HEXO has already signed supply agreements with partners overseas, so I would be expecting an increase in international sales growth in the coming years. In my view, economies of scale, more efficient automated technology, and the integration of new acquisitions will likely lead to lower cost per gram.
Seeking Alpha Dec 14

HEXO Q1 Earnings: Not A Great Path Forward

HEXO reported weak FQ1 results for the period ending Oct. 31. The addition of the businesses of Redecan and 48North didn't improve the financials or move the company any closer to being cash flow positive. The stock isn't touchable with the senior debt overhang and another restructuring in the works.

Revenue & Expenses Breakdown

How HEXO makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:HEXO Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Apr 23124-273611
31 Jan 23148-301861
31 Oct 22177-1,0131053
31 Jul 22191-1,0741223
30 Apr 22187-1,0421284
31 Jan 22164-9181094
31 Oct 21144-228964
31 Jul 21124-115804
30 Apr 21112-214754
31 Jan 21112-213754
31 Oct 2096-491784
31 Jul 2081-546915
30 Apr 2069-4231157
31 Jan 2060-4111196
31 Oct 1956-1171145
31 Jul 1948-701053
30 Apr 1934-35730
31 Jan 1922-30540
31 Oct 189-34410
31 Jul 185-23230
30 Apr 184-12150
31 Jan 184-22120
31 Oct 174-1490
31 Jul 174-1270
30 Apr 174-1570
31 Jan 174-350
31 Oct 163-340
31 Jul 162-340
31 Jul 150-320

Quality Earnings: HEXO is currently unprofitable.

Growing Profit Margin: HEXO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HEXO is unprofitable, and losses have increased over the past 5 years at a rate of 42.2% per year.

Accelerating Growth: Unable to compare HEXO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HEXO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.3%).


Return on Equity

High ROE: HEXO has a negative Return on Equity (-191.4%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/23 05:10
End of Day Share Price 2023/06/22 00:00
Earnings2023/04/30
Annual Earnings2022/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HEXO Corp. is covered by 19 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aaron GreyAlliance Global Partners
David KideckelATB Cormark
Jesse PytlakATB Cormark Historical (Cormark Securities)